842143-97-9

Basic information

• Product Name: (7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile
• Synonyms: (7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile;2-(7-BroMo-1-ethyl-1H-iMidazo[4,5-c]pyridin-2-yl)acetonitrile
• CAS NO: 842143-97-9
• Molecular Formula: C10H9BrN4
• Molecular Weight: 265.10926
• Mol File: 842143-97-9.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: (7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile(842143-97-9)
• EPA Substance Registry System: (7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile(842143-97-9)

Safety Data

• Hazardous Substances Data: 842143-97-9(Hazardous Substances Data)

Usage

General Description

(7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile is a chemical compound with the molecular formula C11H10BrN3. It is a derivative of imidazo[4,5-c]pyridine, which is a heterocyclic compound. (7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile is commonly used in the pharmaceutical industry as a building block for the synthesis of various biologically active molecules. It has also been studied for its potential use in the treatment of various medical conditions, including cancer and infectious diseases. The chemical structure of (7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile makes it a valuable intermediate for the synthesis of complex organic compounds, and it is an important tool for medicinal chemists and pharmaceutical researchers.

Upstream product

• 607371-03-9 5-bromo-N4-ethylpyridine-3,4-diamine 
• 105-56-6 ethyl 2-cyanoacetate 
• 607371-01-7 ethyl-(3-bromo-5-nitropyridin-4-yl)amine 
• 562825-95-0 ethyl-(3-nitropyridin-4-yl)amine 

Downstream Products

• 607370-99-0 4-(7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)oxadiazolidin-3-ylamine 

Relevant articles and documents

MICROBIOCIDAL 4-(IMIDAZO[4,5-C]PYRIDIN-2-YL)-1,2,5-OXADIAZOL-3- AMINE COMPOUNDS HAVING AN OXIME GROUP IN POSITION 7

The present invention provides compounds of formula (I) wherein Y1, Y2, Υ3, Υ4 and Υ5 are as defined in the claims. The invention further relates to compositions which comprise these compounds and to

(1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Further optimisation as highly potent and selective MSK-1-inhibitors

The novel imidazo[4,5-c]pyridine 1,2,5-oxadiazol-3-yl template affords an excellent start point for identification of inhibitors of a number of protein kinases. Here we report on its optimisation for mitogen and stress-activated protein kinase-1 (MSK-1) inhibitory activity, and selectivity over other kinases.

CANCER TREATMENT METHOD

The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a PI3K and/or Akt inhibitor to a mammal suffering from a cancer.